Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1263179

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

Holmes, Frankie A.; Moy, Beverly; Delaloge, Suzette; Chia, Stephen K.L.; Ejlertsen, Bent; Mansi, Janine; Iwata, Hiroji; Gnant, Michael; Buyse, Marc; Barrios, Carlos H. et al.
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial // European Journal of Cancer, 184 (2023), 48-59 doi:10.1016/j.ejca.2023.02.002 (međunarodna recenzija, članak, znanstveni)

CROSBI ID: 1263179 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

Autori
Holmes, Frankie A. ; Moy, Beverly ; Delaloge, Suzette ; Chia, Stephen K.L. ; Ejlertsen, Bent ; Mansi, Janine ; Iwata, Hiroji ; Gnant, Michael ; Buyse, Marc ; Barrios, Carlos H. ; Silovski, Tajana ; Šeparović, Robert ; Bashford, Anna ; Zotano, Angel Guerrero ; Denduluri, Neelima ; Patt, Debra ; Gokmen, Erhan ; Gore, Ira ; Smith, John W. ; Loibl, Sibylle ; Masuda, Norikazu ; Tomašević, Zorica ; Petráková, Katarina ; DiPrimeo, Daniel ; Wong, Alvin ; Martin, Miguel ; Chan, Arlene

Izvornik
European Journal of Cancer (0959-8049) 184 (2023); 48-59

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Breast Neoplasms ; Chemotherapy ; Adjuvant ; Kaplan–Meier estimate ; Neratinib ; Receptor ErbB-2 ; Survival analysis

Sažetak
ExteNET showed that neratinib, an irreversible pan-HER tyrosine ki- nase inhibitor, given for 1 year after trastuzumab-based therapy significantly improved inva- sive disease-free survival in women with early-stage HER2-positive breast cancer. We report the final analysis of overall survival in ExteNET.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA

Ustanove:
Klinika za tumore,
Medicinski fakultet, Osijek,
Sveučilište Jurja Dobrile u Puli

Profili:

Avatar Url Tajana Silovski (autor)

Avatar Url Robert Šeparović (autor)

Poveznice na cjeloviti tekst rada:

doi www.ejcancer.com

Citiraj ovu publikaciju:

Holmes, Frankie A.; Moy, Beverly; Delaloge, Suzette; Chia, Stephen K.L.; Ejlertsen, Bent; Mansi, Janine; Iwata, Hiroji; Gnant, Michael; Buyse, Marc; Barrios, Carlos H. et al.
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial // European Journal of Cancer, 184 (2023), 48-59 doi:10.1016/j.ejca.2023.02.002 (međunarodna recenzija, članak, znanstveni)
Holmes, F., Moy, B., Delaloge, S., Chia, S., Ejlertsen, B., Mansi, J., Iwata, H., Gnant, M., Buyse, M. & Barrios, C. (2023) Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. European Journal of Cancer, 184, 48-59 doi:10.1016/j.ejca.2023.02.002.
@article{article, author = {Holmes, Frankie A. and Moy, Beverly and Delaloge, Suzette and Chia, Stephen K.L. and Ejlertsen, Bent and Mansi, Janine and Iwata, Hiroji and Gnant, Michael and Buyse, Marc and Barrios, Carlos H. and Silovski, Tajana and \v{S}eparovi\'{c}, Robert and Bashford, Anna and Zotano, Angel Guerrero and Denduluri, Neelima and Patt, Debra and Gokmen, Erhan and Gore, Ira and Smith, John W. and Loibl, Sibylle and Masuda, Norikazu and Toma\v{s}evi\'{c}, Zorica and Petr\'{a}kov\'{a}, Katarina and DiPrimeo, Daniel and Wong, Alvin and Martin, Miguel and Chan, Arlene}, year = {2023}, pages = {48-59}, DOI = {10.1016/j.ejca.2023.02.002}, keywords = {Breast Neoplasms, Chemotherapy, Adjuvant, Kaplan–Meier estimate, Neratinib, Receptor ErbB-2, Survival analysis}, journal = {European Journal of Cancer}, doi = {10.1016/j.ejca.2023.02.002}, volume = {184}, issn = {0959-8049}, title = {Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial}, keyword = {Breast Neoplasms, Chemotherapy, Adjuvant, Kaplan–Meier estimate, Neratinib, Receptor ErbB-2, Survival analysis} }
@article{article, author = {Holmes, Frankie A. and Moy, Beverly and Delaloge, Suzette and Chia, Stephen K.L. and Ejlertsen, Bent and Mansi, Janine and Iwata, Hiroji and Gnant, Michael and Buyse, Marc and Barrios, Carlos H. and Silovski, Tajana and \v{S}eparovi\'{c}, Robert and Bashford, Anna and Zotano, Angel Guerrero and Denduluri, Neelima and Patt, Debra and Gokmen, Erhan and Gore, Ira and Smith, John W. and Loibl, Sibylle and Masuda, Norikazu and Toma\v{s}evi\'{c}, Zorica and Petr\'{a}kov\'{a}, Katarina and DiPrimeo, Daniel and Wong, Alvin and Martin, Miguel and Chan, Arlene}, year = {2023}, pages = {48-59}, DOI = {10.1016/j.ejca.2023.02.002}, keywords = {Breast Neoplasms, Chemotherapy, Adjuvant, Kaplan–Meier estimate, Neratinib, Receptor ErbB-2, Survival analysis}, journal = {European Journal of Cancer}, doi = {10.1016/j.ejca.2023.02.002}, volume = {184}, issn = {0959-8049}, title = {Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial}, keyword = {Breast Neoplasms, Chemotherapy, Adjuvant, Kaplan–Meier estimate, Neratinib, Receptor ErbB-2, Survival analysis} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.